Search Results
Your search for ,sIX matches 2928 pages
Showing 501 - 550Addition of Anti–IGF-1R Antibody Ganitumab to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Metastatic Ewing Sarcoma
As reported in the Journal of Clinical Oncology by DuBois et al, the Children’s Oncology Group phase III AEWS1221 trial showed no event-free survival benefit with the addition of the anti–insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody ganitumab to interval-compressed...
Association of Immune-Related Gene-Expression Signatures and TILs With Outcomes in Early-Stage, HER2-Positive Breast Cancer
In a study reported in JAMA Oncology, Aranzazu Fernandez-Martinez, MD, PhD, and colleagues found that several B-cell–related gene signatures provided better prediction of pathologic complete response and event-free survival than tumor-infiltrating lymphocyte (TIL) levels among patients with...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Atrium Health and Wake Forest University School of Medicine Cancer Program Appoint New Director
Atrium Health recently announced that Ruben A. Mesa, MD, FACP, has been named President and Executive Director of its cancer service line—which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center—and Vice Dean for Cancer Programs at...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
Northwell Receives Gift From Trustee Roy J. Zuckerberg to Create First Cancer Hospital and Cancer Campus on Long Island
Northwell Health recently announced a gift from longtime trustee Roy J. Zuckerberg to create the R.J. Zuckerberg Cancer Hospital at Long Island Jewish (LIJ) Medical Center—Long Island’s first cancer hospital—and to establish the R.J. Zuckerberg Cancer Center, Northwell’s largest ambulatory cancer...
How Experts Treat Mantle Cell Lymphoma in First Complete Response
Options are growing in the treatment of mantle cell lymphoma after complete response. At the 2022 Pan Pacific Lymphoma Conference,1 the use of these newer strategies in older patients was discussed by Brad S. Kahl, MD, Professor of Medicine and Director of the Lymphoma Service at Washington...
Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial
The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
FDA Approves Zanubrutinib for CLL or SLL
On January 19, the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA Trial: Treatment-Naive Patients Efficacy in treatment-naive patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer
An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded high complete response rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, according to data presented by Roger Li, MD, lead study investigator and urologic...
Can Women With Two or Three Ipsilateral Breast Cancer Sites Safely Undergo Breast-Conserving Therapy?
Many women with two or three cancerous lesions in the breast can safely undergo lumpectomy followed by radiation therapy, according to the results of a prospective phase II trial reported at the 2022 San Antonio Breast Cancer Symposium.1 In this study, local recurrence rates after breast-conserving ...
Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors
In a single-center phase II trial reported in the Journal of Clinical Oncology, Ludford et al found that neoadjuvant pembrolizumab produced a high pathologic complete response rate and radiographic objective response rate in patients with localized microsatellite instability–high/mismatch...
Study Finds Posoleucel Demonstrated Antiviral Efficacy and Safety Against Viral Infections Following Allogeneic Stem Cell Transplantation
Studies show that viral infections are common causes of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation and can induce a profound immunocompromised state in some patients that may last up to 24 months or longer posttransplant. In an open-label, single-arm,...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
In the phase I/II CodeBreaK 100 trial reported in The New England Journal of Medicine, John H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor sotorasib showed activity in previously treated patients with advanced pancreatic cancer and a KRAS G12C mutation. Study Details In the...
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
First-Line Atezolizumab Plus Bevacizumab in Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden
In a Spanish phase II trial reported in JAMA Oncology, Mariano Provencio, MD, PhD, and colleagues found that the combination of atezolizumab and bevacizumab was active in the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
Crizotinib Combined With Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Lowe et al, findings in an arm of the Children’s Oncology Group phase II ANHL12P1 trial (arm CZ) showed high event-free and overall survival rates with the addition of crizotinib to chemotherapy in newly diagnosed pediatric patients with...
Study Finds Lifileucel Active in Advanced Melanoma After Disease Progression on Immune Checkpoint Inhibitors
Cell therapy with tumor-infiltrating lymphocytes (TIL) may address an important unmet need for patients with difficult-to-treat melanoma after disease progression on immune checkpoint inhibitors, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual ...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer: Agreement Between ICD-Coded and -Adjudicated Events
In a study reported in JACC: CardioOncology, Kondapalli et al found that cardiovascular events common in the general population were observed both prior to and after initiation of immune checkpoint inhibitor therapy for cancer; myocarditis was more common posttreatment, but infrequent. Agreement...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
First-Line Nivolumab/Ipilimumab vs EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer
The final results of the phase III CheckMate 651 trial showed no significant overall survival benefit with first-line nivolumab/ipilimumab vs the EXTREME regimen (cetuximab plus cisplatin or carboplatin plus fluorouracil for up to six cycles, followed by cetuximab maintenance) in recurrent or...
Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer
An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded the “best results seen in the field” in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer, according to data presented during the 2022 Society for Immunotherapy of Cancer...
Adavosertib in Refractory Solid Tumors With CCNE1 Amplification
In a phase II trial reported in the Journal of Clinical Oncology, Fu et al found that the WEE1 kinase inhibitor adavosertib was active in patients with refractory solid tumors with CCNE1 amplification, with evidence of increased activity in epithelial ovarian cancer. Study Details In the trial, 30...
Zanubrutinib Found Superior to Ibrutinib for CLL and SLL
Zanubrutinib showed superior efficacy to ibrutinib—with fewer side effects—in the first head-to-head comparison between the Bruton’s tyrosine kinase (BTK) inhibitors among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented by Jennifer...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
Breast-Conserving Therapy May Be a Treatment Option for Some Patients With Multiple Ipsilateral Breast Lesions
Patients with multiple tumors in a single breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to new findings presented by Judy C. Boughey, MD, and colleagues at the 2022 San...
Experimental Drug Under Study in Liver Cancer
A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer who have been treated unsuccessfully previously with up to three lines of treatment. These findings were presented...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Patient-Reported Outcomes Study Finds Severe Symptoms in Meaningful Minority of Patients With Cancer
Routine monitoring in the real world may help to identify patients with cancer who are experiencing challenging symptoms, without significantly disrupting clinical workload, according to data presented during the 2022 ASCO Quality Care Symposium.1,2 The analysis of nearly 40,000 patient-reported...
Addition of First-Line Atezolizumab to Vemurafenib/Cobimetinib in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statistically nonsignificant improvement with the addition of first-line atezolizumab to vemurafenib and cobimetinib in ...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
DNA Repair Protein MRE11 Expression and Disease-Specific Mortality Among Patients With Muscle-Invasive Bladder Cancer Receiving Trimodality Therapy
In a retrospective analysis reported in JAMA Network Open, Magliocco et al found that among patients with muscle-invasive bladder cancer receiving bladder-preserving trimodality therapy, those with a lower expression of the DNA repair protein MRE11 had significantly poorer disease-specific...
Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care?
In an Australian phase IIb trial (MedCan1-CBD) reported in the Journal of Clinical Oncology, Hardy et al found that use of cannabidiol (CBD) oil did not improve symptom distress vs placebo in adult patients with advanced cancer receiving palliative care. Study Details The double-blind multicenter...
Novel Bispecific Antibody Zanidatamab in Advanced HER2-Expressing or HER2-Amplified Cancers
In a phase I dose-escalation and expansion study reported in The Lancet Oncology, Funda Meric-Bernstam, MD, and colleagues found that zanidatamab, a novel bispecific monoclonal antibody directed against two nonoverlapping domains of HER2, showed activity in locally advanced or metastatic...
Importance of Screening Programs in Diagnosing Cancer in Patients With Type 2 Diabetes
Researchers have discovered that patients with type 2 diabetes who develop cancer are more likely to be diagnosed with advanced disease if they do not undergo routine screenings, according to a new study published by Jansana et al in the European Journal of Cancer. The new findings were also...
Researchers Find Changes in Blood Proteins up to 2 Years Before Breast Cancer Diagnosis
Researchers have found changes in the levels of particular proteins in patients’ blood up to 2 years before they were diagnosed with breast cancer, according to a novel study published by Hagenaars et al in the European Journal of Cancer. The study, also presented at the 13th European Breast Cancer ...
Comparison of Bevacizumab Durations in Front-Line Therapy for Advanced Ovarian Cancer
In a European phase III trial (AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15) reported in the Journal of Clinical Oncology, Jacobus Pfisterer, MD, PhD, and colleagues found no significant progression-free survival benefit with the extension of bevacizumab treatment from 15 to 30 months in patients...
POSEIDON Trial: First-Line Durvalumab With or Without Tremelimumab Plus Chemotherapy in Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Melissa L. Johnson, MD, and colleagues, the pivotal phase III POSEIDON trial has shown significantly improved progression-free and overall survival with the addition of tremelimumab and durvalumab to platinum-based chemotherapy in the first-line...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
Selpercatinib Approved for Advanced RET Fusion–Positive Solid Tumors and Advanced RET Fusion–Positive NSCLC
On September 21, 2022, selpercatinib was granted accelerated approval for adults with locally advanced or metastatic solid tumors with RET gene fusion whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.1 On the same day,...
First-Line Pembrolizumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC Without EGFR/ALK Alterations
As reported in the Journal of Clinical Oncology by Gilberto de Castro, Jr, MD, PhD, and colleagues, 5-year follow-up of the KEYNOTE-042 trial showed a maintained overall survival benefit with first-line pembrolizumab vs chemotherapy in patients with non–small cell lung cancer (NSCLC) with a PD-L1...
Comparison of Two Chemotherapy Regimens for Newly Diagnosed Ewing Sarcoma
As reported in The Lancet by Brennan et al, the European phase III EURO EWING 2012 trial found improved event-free survival with a standard U.S. chemotherapy regimen vs a standard European regimen in newly diagnosed patients with Ewing sarcoma. As stated by the investigators, “Internationally, a...
